WARRANT TO PURCHASE COMMON STOCK GREENWICH LIFESCIENCES, INC.Greenwich LifeSciences, Inc. • June 23rd, 2020 • Pharmaceutical preparations
THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after _____________, 2021 (the “Initial Exercise Date”) and, in accordance with FINRA Rule 5110(f)(2)(G)(i), prior to at 5:00 p.m. (New York time) on _____________, 2025 (the “Termination Date”), but not thereafter, to subscribe for and purchase from Greenwich LifeSciences, Inc., a Delaware corporation (the “Company”), up to _______________1 shares of common stock, par value $0.001 per share (the “Common Stock”), of the Company (the “Warrant Shares”), as subject to adjustment hereunder. The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
GREENWICH LIFESCIENCES, INC. UNDERWRITING AGREEMENT 660,000 Shares of Common StockUnderwriting Agreement • December 22nd, 2020 • Greenwich LifeSciences, Inc. • Pharmaceutical preparations • New York
GREENWICH LIFESCIENCES, INC. UNDERWRITING AGREEMENT ______ Shares of Common StockUnderwriting Agreement • September 9th, 2020 • Greenwich LifeSciences, Inc. • Pharmaceutical preparations • New York
GREENWICH LIFESCIENCES, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom Aegis Capital Corp. is acting as representative (the “Representative”), an aggregate of ______ authorized but unissued shares of common stock, par value $0.001 per share, (the “Common Stock”) of the Company (the “Firm Shares”). The Company also proposes to sell to the Underwriters, upon the terms and conditions set forth in Section 4 hereof, up to an additional ______ shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter collectively referred to as the “Shares” or the “Securities”.
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • July 12th, 2022 • Greenwich LifeSciences, Inc. • Pharmaceutical preparations • New York
GREENWICH LIFESCIENCES, INC. UNDERWRITING AGREEMENT 1,260,870 Shares of Common StockUnderwriting Agreement • September 28th, 2020 • Greenwich LifeSciences, Inc. • Pharmaceutical preparations • New York
GREENWICH LIFESCIENCES, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom Aegis Capital Corp. is acting as representative (the “Representative”), an aggregate of 1,260,870 authorized but unissued shares of common stock, par value $0.001 per share, (the “Common Stock”) of the Company (the “Firm Shares”). The Company also proposes to sell to the Underwriters, upon the terms and conditions set forth in Section 4 hereof, up to an additional 189,130 shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter collectively referred to as the “Shares” or the “Securities”.
GREENWICH LIFESCIENCES, INC. UNDERWRITING AGREEMENT ____________ Shares of Common StockUnderwriting Agreement • December 15th, 2020 • Greenwich LifeSciences, Inc. • Pharmaceutical preparations • New York
GREENWICH LIFESCIENCES, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom Aegis Capital Corp. is acting as representative (the “Representative”), an aggregate of ____________ authorized but unissued shares of common stock, par value $0.001 per share, (the “Common Stock”) of the Company (the “Firm Shares”). The Company also proposes to sell to the Underwriters, upon the terms and conditions set forth in Section 4 hereof, up to an additional ____________ shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter collectively referred to as the “Shares” or the “Securities”.
AT THE MARKET OFFERING AGREEMENTMarket Offering Agreement • October 7th, 2024 • Greenwich LifeSciences, Inc. • Pharmaceutical preparations • New York
Greenwich LifeSciences, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows:
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • October 1st, 2020 • Greenwich LifeSciences, Inc. • Pharmaceutical preparations • Delaware
This Executive Employment Agreement (the “Agreement”) is made and entered into effective as of September 29, 2020 (the “Effective Date”), by and between Snehal Patel (the “Executive”) and Greenwich Lifesciences, Inc., a Delaware corporation (the “Company”).
Registration Rights AgreementRegistration Rights Agreement • June 23rd, 2020 • Greenwich LifeSciences, Inc. • Pharmaceutical preparations • New York
This Registration Rights (this “Agreement”) is made and entered into as of July 23, 2010 (the “Effective Date”) by and among Norwell, Inc., a Delaware corporation (the “Company”) and the holders of Series A Preferred Stock (the “Series A Preferred Stock”) as set forth on Exhibit A hereto (the “Holders” or the “Investors”).
INDEMNIFICATION AGREEMENTIndemnification Agreement • May 29th, 2020 • Greenwich LifeSciences, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of , between Greenwich LifeSciences, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
EXCLUSIVE LICENSE AGREEMENT BETWEEN THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. AND NORWELL, INC.Exclusive License Agreement • June 23rd, 2020 • Greenwich LifeSciences, Inc. • Pharmaceutical preparations • Maryland
THIS EXCLUSIVE LICENSE AGREEMENT is entered into as of the 24th day of April, 2009 (the “Effective Date”), by and between The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., a tax-exempt corporation organized under the laws of the State of Maryland and having its principal offices at 1401 Rockville Pike, Suite 600, Rockville, Maryland 20852 (the “Foundation”) and Norwell, Inc., a corporation organized under the laws of the State of Delaware and having its principal offices at 415 Jackson Hill, Houston, Texas (“Licensee”). The Foundation and Licensee sometimes are referred to collectively herein as the “Parties” or individually as a “Party.”
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 17th, 2024 • Greenwich LifeSciences, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 13th, 2024 (the “Effective Date”), between Greenwich LifeSciences, Inc., a Delaware corporation (the “Company”), and the purchaser identified on the signature page hereto (each, including its successors and assigns, a “Purchaser”).
